PGF2alpha, Natriuretic Peptides, and IOP
About the Research Project
Program
Award Type
Standard
Award Amount
$70,000
Active Dates
April 01, 2004 - January 31, 2007
Grant ID
G2004050
Summary
Dr. Hussein is seeking ways that the outflow of aqueous humor in the eye can be regulated through the actions of metalloproteinases (a family of zinc-dependent enzymes) in the trabecular meshwork. He has hypothesized that the enzyme PGF2a reduces intraocular pressure through the release of natriuretic peptides on cells in the anterior segment and the subsequent secretion of matrix metalloproteinases (MMPs). He hopes to elucidate the effects of PGF2a on the release of natriuretic peptides from cells in the ciliary body, and to describe the effect of these peptides on MMP-secretion in human ciliary muscle cells. He then plans to determine the effects of both PGF2a and natriuretic peptide modulation on the IOP. The long-term goal of this research is to focus on how tissues in the anterior segment of the eye act in a coordinated fashion to regulate intraocular pressure in normal individuals. This will lay the groundwork for subsequent studies investigating how changes in the expression of specific proteins alter these regulatory and cell-signaling events in individuals with glaucoma.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute